Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

84.11B

Market cap84.11B

Price-Earnings ratio

20.10

Price-Earnings ratio20.10

Dividend yield

0.45%

Dividend yield0.45%

Average volume

621.36K

Average volume621.36K

High today

$830.20

High today$830.20

Low today

$814.63

Low today$814.63

Open price

$826.14

Open price$826.14

Volume

224.45K

Volume224.45K

52 Week high

$859.34

52 Week high$859.34

52 Week low

$591.52

52 Week low$591.52

Stock Snapshot

The current Regeneron(REGN) stock price is $817.00, with a market capitalization of 84.11B. The stock trades at a price-to-earnings (P/E) ratio of 20.10 and offers a dividend yield of 0.45%.

During the trading session on 2026-10-29, Regeneron(REGN) shares reached a daily high of $830.20 and a low of $814.63. At a current price of $817.00, the stock is +0.3% higher than the low and still -1.6% under the high.

Trading volume for Regeneron(REGN) stock has reached 224.45K, versus its average volume of 621.36K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $591.52.

REGN News

Barchart 7h

What to expect from Regeneron’s Q3 earnings - Barchart.com

...

Simply Wall St 2d

How Inmazeb Deal Extension Will Impact Regeneron Stock

Regeneron Pharmaceuticals extended its BARDA agreement to supply additional Inmazeb Ebola treatment through 2031 for about US$270 million, while also reporting...

24/7 Wall St. 3d

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings

Investing Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings Regeneron (NASDAQ:REGN | REGN Price Prediction) reports...

Analyst ratings

65%

of 31 ratings

Buy

64.5%

Hold

29%

Sell

6.5%

More REGN News

Simply Wall St 3d

Regeneron Pharmaceuticals Could Be 5% Undervalued Following Fresh Libtayo Phase 3 Data

Regeneron Pharmaceuticals (REGN) is back in focus after late-breaking C POST Phase 3 data at ESMO 2026 showed sustained disease-free survival and emerging overa...

Simply Wall St 6d

Regeneron Pharmaceuticals Pushes Ahead In Weight Loss With Two Distinct Drug Bets

Regeneron Pharmaceuticals (NasdaqGS:REGN) reported progress on two obesity drug candidates, olatorepatide and trevogrumab, in October 2026. Internal data indic...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.